The NIH has stopped a part of a 10,251-patient study seeking the best strategy to prevent heart attack, stroke or death from cardiovascular disease among Type 2 diabetes patients. The decision was made after the finding of more deaths among those who took an aggressive approach to cutting blood-sugar levels than among those who used a moderate strategy. Researchers have yet to identify the cause for the higher death rate, and said they found no evidence linking the increase to diabetes drugs metformin and glitazones, or to any other drug.

Related Summaries